|
Home | Search Global IT News:
|
|
|
|
|
IT News & Press Release Distribution:
|
|
|
(IT-NEWSWIRE.COM, June 01, 2017 ) Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 30 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 15 molecules, respectively.
Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/escherichia-coli-infections-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease) .
- The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001799299/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Abgentis Ltd
Adenium Biotech ApS
AstraZeneca Plc
Atterx Biotherapeutics Inc
AvidBiotics Corp
Cellceutix Corp
ContraFect Corp
Debiopharm International SA
Emergent BioSolutions Inc
F. Hoffmann-La Roche Ltd
GangaGen Inc
Hsiri Therapeutics LLC
ImmunoClin Corp
Immuron Ltd
Johnson & Johnson
Kyorin Pharmaceutical Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Nabriva Therapeutics AG
Navigen Inc
Nosopharm SAS
Novabiotics Ltd
Paratek Pharmaceuticals Inc
Pherecydes Pharma SA
Phico Therapeutics Ltd
Recce Ltd
Sealife PHARMA GMBH
Soligenix Inc
Syntiron LLC
Tetraphase Pharmaceuticals Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001799299/discount
List of Tables
Number of Products under Development for Escherichia coli Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Escherichia coli Infections - Pipeline by Abgentis Ltd, H1 2017
Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H1 2017
Escherichia coli Infections - Pipeline by AstraZeneca Plc, H1 2017
Escherichia coli Infections - Pipeline by Atterx Biotherapeutics Inc, H1 2017
Escherichia coli Infections - Pipeline by AvidBiotics Corp, H1 2017
Escherichia coli Infections - Pipeline by Cellceutix Corp, H1 2017
Escherichia coli Infections - Pipeline by ContraFect Corp, H1 2017
Escherichia coli Infections - Pipeline by Debiopharm International SA, H1 2017
Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Escherichia coli Infections - Pipeline by GangaGen Inc, H1 2017
Escherichia coli Infections - Pipeline by Hsiri Therapeutics LLC, H1 2017
Escherichia coli Infections - Pipeline by ImmunoClin Corp, H1 2017
Escherichia coli Infections - Pipeline by Immuron Ltd, H1 2017
Escherichia coli Infections - Pipeline by Johnson & Johnson, H1 2017
Escherichia coli Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
Escherichia coli Infections - Pipeline by Merck & Co Inc, H1 2017
Escherichia coli Infections - Pipeline by Microbiotix Inc, H1 2017
Escherichia coli Infections - Pipeline by Nabriva Therapeutics AG, H1 2017
Escherichia coli Infections - Pipeline by Navigen Inc, H1 2017
Escherichia coli Infections - Pipeline by Nosopharm SAS, H1 2017
Escherichia coli Infections - Pipeline by Novabiotics Ltd, H1 2017
Escherichia coli Infections - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
Escherichia coli Infections - Pipeline by Pherecydes Pharma SA, H1 2017
Escherichia coli Infections - Pipeline by Phico Therapeutics Ltd, H1 2017
Escherichia coli Infections - Pipeline by Recce Ltd, H1 2017
Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H1 2017
Escherichia coli Infections - Pipeline by Soligenix Inc, H1 2017
Escherichia coli Infections - Pipeline by Syntiron LLC, H1 2017
Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Escherichia coli Infections - Dormant Projects, H1 2017
Escherichia coli Infections - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Escherichia coli Infections - Dormant Projects, H1 2017 (Contd..2) , H1 2017
Escherichia coli Infections - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001799299/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
|
Information Technology (IT) Advertisement
|
|
|
|
|
Information Technology Sponsors
|
|
|
|
|
